Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Sign up freePricing

Sv Life Sciences Fund Vi Strategic Partners, L.P. investment portfolio

Sv Life Sciences Fund Vi Strategic Partners, L.P. has made numerous investments in companies such as Enara Bio, Artios Pharma, and Sitryx Therapeutics within the Healthcare & Life Sciences sector.

vc
Portfolio
3
Team
0

Portfolio (3)

CompanySectorCitySourceLast confirmed on
Artios Pharma Limited
Artios Pharma Limited develops DNA‑damage‑response‑based cancer therapeutics. Its pipeline includes the ATR inhibitor alnodesertib and the Polθ inhibitor ART6043, targeting hard‑to‑treat solid tumours.
Healthcare & Life SciencesCambridgeConfirmed2025-12-28
Enara Bio Limited
Enara Bio is a biotechnology company that discovers novel “Dark Antigen” cancer targets and develops bispecific T‑cell engager immunotherapies for solid tumours. It collaborates with pharmaceutical partners such as Boehringer Ingelheim to advance these therapies toward clinical trials.
Healthcare & Life SciencesOxfordConfirmed2025-11-07

Sign up to see the full portfolio

+1 more company

Sign up

Shareholding changes (4)

Sv Life Sciences Fund Vi Strategic Partners, L.P.'s positions across portfolio companies
2025
  • 12-28AddedArtios Pharma Limited
    • SERIES D SHARES 0 → 117,118
    • SERIES D1 SHARES 0 → 24,044
  • 11-07IncreasedEnara Bio Limited
    • SERIES A PREFERRED 200,566 → 283,454
    • SERIES A-1 PREFERRED 46,172 → 65,254
    • SERIES B-1 PREFERRED 149,432 → 242,827

Sign up free to see when this investor has bought or sold shares.

+2 more changes

Sign up